Humacyte FY2024 EPS Forecast Boosted by Cantor Fitzgerald

Humacyte, Inc. (NASDAQ:HUMA) – Stock analysts at Cantor Fitzgerald increased their FY2024 EPS estimates for Humacyte in a note issued to investors on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($1.40) for the year, up from their previous estimate of ($1.41). Cantor Fitzgerald has a “Overweight” rating and a $13.00 price target on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

A number of other research analysts have also issued reports on the company. BTIG Research reiterated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Benchmark increased their price objective on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. HC Wainwright reissued a “buy” rating and set a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Monday. Finally, Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $13.71.

Humacyte Trading Down 2.2 %

NASDAQ HUMA opened at $4.48 on Friday. The stock has a market capitalization of $563.85 million, a price-to-earnings ratio of -3.34 and a beta of 1.32. Humacyte has a twelve month low of $2.48 and a twelve month high of $9.97. The stock has a 50-day moving average of $4.60 and a 200 day moving average of $5.66.

Insider Activity at Humacyte

In related news, CEO Laura E. Niklason sold 261,369 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,500,000 shares of company stock valued at $6,606,799. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HUMA. Brookstone Capital Management purchased a new stake in shares of Humacyte in the 4th quarter valued at $56,000. ACT Wealth Management LLC acquired a new position in Humacyte in the 4th quarter valued at about $57,000. Concurrent Investment Advisors LLC purchased a new stake in Humacyte during the third quarter worth about $75,000. FORA Capital LLC acquired a new stake in shares of Humacyte during the third quarter worth about $96,000. Finally, Profund Advisors LLC purchased a new position in shares of Humacyte in the second quarter valued at approximately $97,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.